Search

A public-private consortium led by the biotechnology company Nuage Therapeutics, together with the Spanish National Cancer Research Center (CNIO), the European Molecular Biology Laboratory (EMBL) and

The third and final round of trilogues begins to finalize an agreement on the Regulation on plants obtained through New Genomic Techniques (NGTs) and the food and feed derived from them.

Meet BePharma Institute, our new memeber. We spoke with Pedro Gonzáles Sánchez, manager.

Meet Neural Omega, our new member. We spoke with Pedro Bernardo Martín-Borregon, Founder & CEO.

Joan Puig, a graduate in Pharmacy and in Business Administration and Management, and with a General Management Programme (PDG) from IESE, has an extensive background in the field of analytical and

The aim of this document is to promote a specific regulatory framework that recognises these technologies as a strategic sector for the country’s technological autonomy and competitiveness, as well as

In 2021, antimicrobial resistance was involved in at least 4.7 million deaths worldwide, with 35,000 annual deaths in Europe and nearly 4,000 in Spain.

Recent research links persistent inflammatory status to metabolic, neurodegenerative and cardiovascular pathologies.

The net result as of September 30, 2025 improved by $1.1M compared to September 2024, following termination of a Convertible Bonds financing facility with Nice&Green

Harmonizing regulation, improving access to funding and talent, advancing biomanufacturing and artificial intelligence, and strengthening Europe’s strategic autonomy to build a more competitive

The Bizkaia-based biotechnology company received the award at the Royal Palace of El Pardo (Madrid), at a ceremony presided over by Queen Letizia

Meet our new member Cencora Pharmalex. We spoke with Gonzalo Casino Fernández, Director General Cencora Pharmalex Iberia.

Preclinical data for VCN-12, the next candidate from Theriva’s VCN-X discovery program, highlight a novel mechanism of action with the potential to significantly improve antitumor effects

VCN-01 expanded mPDAC data from VIRAGE Phase 2b trial to be presented at ESMO 2025

The public research institutes, together with the units and groups of the University of Barcelona (UB) present at the Barcelona Science Park (PCB-UB), have reached a new funding record in 2024. This

The investment will enable Qida to boost growth, technological innovation, and the attraction of top talent, with the goal of reaching more than 100,000 people served and quadrupling sales within

Recently approved by the European Medicines Agency, RESTORE will evaluate iadademstat’s ability to raise fetal hemoglobin (HbF) in adult patients with SCD

BCN HEALTH has published in the Journal of Medical Economics a study analyzing the incidence, management, and associated costs of chronic kidney disease (CKD) in Spain between 2011 and 2017. Based on

The company expects to close the year with sales exceeding €50 million and an EBITDA above €20 million

AptaTargets signed in May 2025 a licensing agreement with Merck for the clinical development and global commercialisation of ApTOLL, an aptamer with neuroprotective effect for the treatment of

Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its management will participate at the following upcoming events: